{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:13:27Z","timestamp":1792790007842,"version":"4.5.0"},"reference-count":26,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zentiva k.s"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Omeprazole undergoes degradation in acidic conditions, which makes it unstable in low pHs found in the gastric environment. The vast majority of already marketed omeprazole formulations use enteric polymer coatings to protect the drug from exposure to acidic pH in the stomach, allowing for drug release in the small intestine where the pH is higher. This study aimed to explore the technical aspects of using stomach acid neutralizers as an alternative to polymeric coatings for omeprazole. Methods: After evaluating various neutralizers, magnesium oxide and sodium bicarbonate were chosen to be incorporated into capsules containing omeprazole, which then underwent in vitro dissolution testing to assess their ability to maintain optimal pH levels and ensure appropriate dissolution kinetics. Hygroscopicity and chemical stability of the selected formulation were tested to prove pharmaceutical quality of the product. An in vivo pharmacokinetic study was conducted to demonstrate the efficacy of the omeprazole\u2013sodium bicarbonate formulation in providing faster absorption in humans. Results: Sodium bicarbonate was selected as the most suitable antacid for ensuring omeprazole stabilization. Its quantity was optimized to effectively neutralize stomach acid, facilitating the rapid release and absorption of omeprazole. In vitro studies demonstrated the ability of the formulation to neutralize gastric acid within five minutes. In vivo studies indicated that maximum concentrations of omeprazole were achieved within half an hour. The product met the requirements of pharmaceutical quality. Conclusions: An easily manufacturable, fast-absorbing oral formulation was developed as an alternative to enteric-coated omeprazole.<\/jats:p>","DOI":"10.3390\/pharmaceutics17020161","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T04:59:10Z","timestamp":1737953950000},"page":"161","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acid-Neutralizing Omeprazole Formulation for Rapid Release and Absorption"],"prefix":"10.3390","volume":"17","author":[{"given":"Sreela","family":"Ramesh","sequence":"first","affiliation":[{"name":"Zentiva, k.s., U Kabelovny 130, 10237 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edt","family":"Zvon\u00ed\u010dek","sequence":"additional","affiliation":[{"name":"Zentiva, k.s., U Kabelovny 130, 10237 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"P\u011b\u010dek","sequence":"additional","affiliation":[{"name":"Zentiva, k.s., U Kabelovny 130, 10237 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00e9ta","family":"Pi\u0161lov\u00e1","sequence":"additional","affiliation":[{"name":"Zentiva, k.s., U Kabelovny 130, 10237 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Ber\u00e1nek","sequence":"additional","affiliation":[{"name":"Zentiva, k.s., U Kabelovny 130, 10237 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Zentiva, k.s., U Kabelovny 130, 10237 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2347-1409","authenticated-orcid":false,"given":"Aleksandra","family":"Dumicic","sequence":"additional","affiliation":[{"name":"Zentiva, k.s., U Kabelovny 130, 10237 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Off. J. Am. Coll. Gastroenterol. |ACG"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/gut.2004.051821","article-title":"Epidemiology of gastro-oesophageal reflux disease: A systematic review","volume":"54","author":"Dent","year":"2005","journal-title":"Gut"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41572-021-00287-w","article-title":"Gastro-oesophageal reflux disease","volume":"7","author":"Fass","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21501327211046736","DOI":"10.1177\/21501327211046736","article-title":"The medical Management of Gastroesophageal Reflux Disease: A narrative review","volume":"12","author":"Lukens","year":"2021","journal-title":"J. Prim. Care Community Health"},{"key":"ref_5","unstructured":"Salisbury, B.H., and Terrell, J.M. (2018). Antacids. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"03000605221086457","DOI":"10.1177\/03000605221086457","article-title":"Antacids revisited: Review on contemporary facts and relevance for self-management","volume":"50","author":"Garg","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: A comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/00365528909091236","article-title":"The gastric H+, K+-ATPase: The site of action of omeprazole","volume":"24","author":"Sachs","year":"1989","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2036.2005.02714.x","article-title":"Similarities and differences among delayed-release proton-pump inhibitor formulations","volume":"22","author":"Horn","year":"2005","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Maderuelo, C., Lanao, J.M., and Zarzuelo, A.A. (2022). Formulation of dosage forms with proton pump inhibitors: State of the art, challenges and future perspectives. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102043"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105019","DOI":"10.1016\/j.ejps.2019.105019","article-title":"Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability","volume":"138","author":"Maderuelo","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJM199104043241406","article-title":"Omeprazole","volume":"324","author":"Maton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nrd1010","article-title":"A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole","volume":"2","author":"Olbe","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/jm00158a001","article-title":"The mechanism of action of the antisecretory agent omeprazole","volume":"29","author":"Lindberg","year":"1986","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jppr1998283174","article-title":"Nasogastric administration of omeprazole","volume":"28","author":"Elliott","year":"1998","journal-title":"Aust. J. Hosp. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1039\/C9NJ00932A","article-title":"Identification and structural characterization of the stress degradation products of omeprazole using Q-TOF-LC-ESI-MS\/MS and NMR experiments: Evaluation of the toxicity of the degradation products","volume":"43","author":"Shankar","year":"2019","journal-title":"New J. Chem."},{"key":"ref_17","unstructured":"(2024, July 07). Medsafe, Available online: https:\/\/www.medsafe.govt.nz\/consumers\/cmi\/l\/losec.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.dld.2006.01.032","article-title":"Acid-suppressive effects of generic omeprazole: Comparison of three brands of generic omeprazole with original omeprazole","volume":"38","author":"Shimatani","year":"2006","journal-title":"Dig. Liver Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-017-0138-5","article-title":"Erroneous formulation of delayed-release omeprazole capsules: Alert for importing countries","volume":"18","author":"Rahman","year":"2017","journal-title":"BMC Pharmacol. Toxicol."},{"key":"ref_20","unstructured":"(2024, July 04). RxList. Available online: https:\/\/www.rxlist.com\/zegerid-drug.htm."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Walker, D., Ng Kwet Shing, R., Jones, D., Gruss, H.J., and Regu\u0142a, J. (2015). Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: A phase III, randomized study of Zegerid versus Losec. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116308"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.2147\/DDDT.S212491","article-title":"The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg\/sodium bicarbonate 800 mg in healthy adult male","volume":"13","author":"Kim","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_23","unstructured":"(2024, July 10). European Medicines Agency, Guideline on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products CPMP\/QWP\/122\/02. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products-revision-1-corr_en.pdf."},{"key":"ref_24","unstructured":"(2024, August 01). Europeian Pharmacopoeia. Available online: https:\/\/www.drugfuture.com\/Pharmacopoeia\/EP7\/DATA\/0942E.PDF."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/00365520600610451","article-title":"Effects of posture on the physiology of gastric emptying: A magnetic resonance imaging study","volume":"41","author":"Steingoetter","year":"2006","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1021\/mp100149j","article-title":"Physiological parameters for oral delivery and in vitro testing","volume":"7","author":"Mudie","year":"2010","journal-title":"Mol. Pharm."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/2\/161\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:03Z","timestamp":1759919763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/2\/161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["pharmaceutics17020161"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17020161","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]}}}